Short answer
AbbVie Inc (ABBV) filed an 8-K current report with the SEC on April 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only signature and Inline XBRL cover-page references.
AbbVie Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature and Inline XBRL cover-page references
- No earnings figures or operating results provided in the supplied Item 2.02 text
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $15.002B, up 12.4%; adjusted EPS $2.65, up 7.7%, signaling strong operating momentum
- Immunology growth led by Skyrizi $4.483B, up 30.9%, and Rinvoq $2.119B, up 23.3%; Humira fell 38.6%
- Neuroscience revenue $2.875B, up 26.0%, with Qulipta up 53.6% and Ubrelvy up 41.4%
- GAAP EPS fell 45.8% to $0.39, pressured by $744M acquired IPR&D and milestone expense
- 2026 adjusted EPS guidance raised to $14.08-$14.28 from $13.96-$14.16; trenibotulinumtoxinE FDA setback limited to manufacturing information
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AbbVie Inc 8-K filings
Get the next ABBV 8-K as it lands
Follow ABBV for push alerts, or ask the research agent what this filing means.